Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial shows.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight.

Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes former FDA Commissioner @ScottGottliebMD.

On a spring day this year, the New Jersey State Policemen’s Benevolent Association received three unusual visitors: pharmaceutical representatives from Eli Lilly.Lilly’s reps presented a slide deck that laid out data on the effectiveness of Lilly’s weight-loss drug Zepbound.

A survey by consulting firm Mercer shows that close to half of U.S. companies with more than 500 employees now cover drugs such as Wegovy, Ozempic, and Zepbound.